Comparison · NCT05011513-sae
Nirmatrelvir 300 mg + Ritonavir 100 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nirmatrelvir 300 mg + Ritonavir 100 mg vs Placebo: serious adverse events. Trial comparisons, record NCT05011513-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05011513-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0122 | 0.00621 | 0.024 | wilson | |
| Risk in group 2 | 0.0205 | 0.012 | 0.0348 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00827 | -0.0238 | 0.00619 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.597 | 0.249 | 1.43 | log | |
| Odds ratio, group 1 over group 2 | 0.592 | 0.244 | 1.44 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Nirmatrelvir 300 mg + Ritonavir 100 mg than on Placebo | 121 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nirmatrelvir 300 mg + Ritonavir 100 mg | Participants were randomized to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5. | 8 | 654 | EG000 |
| Group 2 | Placebo | Participants were randomized to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5. | 13 | 634 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- SAEs and Non-SAEs: From Day 1 to Week 24; All-cause mortality: till Week 24
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
- NCT number
- NCT05011513
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19
- Interventions
- PF-07321332, Ritonavir, Placebo, Placebo
- Lead sponsor
- Pfizer
- Results first posted
- 2023-08-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05011513?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05011513-sae